GSC
UTHR icon

Ground Swell Capital’s United Therapeutics UTHR Stock Holding History

Ground Swell Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,191
Closed -$499K – 182
2025
Q3 		$499K Buy
+1,191
New +$401K 1.09% 28
2022
Q4 		– Sell
-1,119
Closed -$234K – 141
2022
Q3 		$234K Buy
+1,119
New +$250K 0.67% 43

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Ground Swell Capital's UTHR Position: Q4 2025 in Review

Ground Swell Capital sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 1,191 shares — an estimated $499K sold.

Ground Swell Capital first reported a position in UTHR in Q3 2022 and held it in 2 quarters. The position peaked at $499K in Q3 2025. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Ground Swell Capital reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ground Swell Capital sold 1,191 United Therapeutics shares in Q4 2025, an estimated $499K.
  • Ground Swell Capital first reported a position in United Therapeutics in Q3 2022 and held it in 2 quarters.
  • Ground Swell Capital's United Therapeutics position peaked at $499K in Q3 2025.
  • 837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Ground Swell Capital's 13F filing for Q4 2025, filed 4 Feb 2026.